CORRESPONDENCE

Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths

© The Author(s) 2021

Dear Editor,

Telomere biology disorders (TBDs) are accelerated aging syndromes affecting hematopoietic, pulmonary, hepatobiliary, and/or immunological systems among others [1, 2]. Adult-onset TBDs are commonly associated with pathogenic variants in TERT and TERCA, and manifest with varying degree of organ involvement such as idiopathic interstitial pneumonia (IIP), cryptogenic cirrhosis, unexplained bone marrow failure (BMF) and/or immunodeficiency, and an inherent risk for cancer development such as myeloid leukemias and squamous cell carcinomas among others [3-9]. Though fluorescence in-situ hybridization (FlowFISH)-determined age-adjusted lymphocyte TL > 50 %tile have a 100% negative predicted value for variant detection, the TL threshold below which genetic screening should be pursued (especially in older patients) is still not known [10, 11]. The optimal TL threshold for variant detection depends on age, with individuals at ages <20 years showing strong correlations with lower TL, while the TL in older variant carriers often overlaps with the lower decile of normal controls [10]. Genetic screening is suggested for TL ≤ 10th centile in lymphocytes or granulocytes, especially in the presence of suggestive personal or family history of a TBD [1]. However, the utility of genetic testing for adult patients with TL > 10th centile and integration of clinical phenotype is currently unclear. Additionally, natural outcomes and diagnostic algorithms are less clear in adult (age ≥ 18 years) patients with short telomeres (defined as TL ≤ 10th centile in lymphocytes).

We retrospectively abstracted data from patients who underwent FlowFISH testing at our institution from years 2015 to 2020. All patients who underwent FlowFISH testing had a suspected clinical phenotype based on at least one or more of the salient clinical features mentioned below. FlowFISH assessments were done at reference laboratories in Vancouver (RepeatDx; Canada) and Johns Hopkins University (JHU, USA). In order to objectively quantify clinical risk, a clinical likelihood score (CLS) was developed based on the number of presenting clinical features suggestive of TBD (prior to FlowFISH testing), or the presence of a significant family history of the same in one or more 1st or 2nd degree relatives, with categories including low (none or 1), intermediate (2), or high risk (≥2), respectively (Supplementary Methods). Salient clinical features were pre-determined as, personal history of premature hair graying (onset at age <30 years), idiopathic interstitial pneumonia (IIP), or IIP/emphysema overlap, cryptogenic cirrhosis or nodular regenerative hyperplasia (NRH), persistent unexplained cytopenias [defined as low blood counts in one or more cell lineages (red or white blood cell or platelets), persistent for 6 months or longer], and/or immunodeficiency.

Genetic testing was performed using either an in-house research-based whole exome sequencing (WES) or commercial bone marrow failure-specific targeted next generation sequencing (NGS) panel or exome-based customized panels (ES-Slices) (Supplementary table 1). Whole-exome sequencing (WES) was performed at the Clinical Genomics Laboratory (Mayo Clinic) using a previously published protocol [12, 13]. Genomic data was processed through an in-house bioinformatics pipeline and analyzed by the Translational Omics Program at the Center for Individualized Medicine (Mayo Clinic) using Emedgene analysis software (Emedgene Technologies).

Two hundred and fifty-two patients at our institution underwent TL assessment at RepeatDx (n = 71) and JHU (n = 181) laboratories. Median age was 57 (range: 4–83) years; 144 (57%) being males; 236 (94%) adults. Significant family history was present in 66 (26%) patients, while premature graying of hair was present in 24 (10%) patients. Organ-specific clinical features included cytopenias (n = 117, 46%), IIP (n = 135, 54%), gastrointestinal disease (n = 38 (15%), cryptogenic cirrhosis-30, NRH-4, enteropathy-2, steatosis-2), and immunodeficiency (n = 37, 15%). Patterns of IIP included 41 (30%) usual interstitial pneumonia (UIP), 15 (11%) non-specific interstitial pneumonia (NSIP), 9 (7%) chronic hypersensitivity pneumonitis (CHP), 2 (1.5%) lymphocytic interstitial pneumonitis and 1 desquamative interstitial pneumonitis. History of smoking was present in 80 (32%) patients, with a median of 24 (0.5–210) pack years of smoking and correlated with IIP (P = 0.01). Emphysematous changes were seen in 15 (11%) patients; 67% in smokers [median, 29 (2.5–70) pack years]. Pulmonary function test information was available in 148 [59%, 108 (80%) in patients with pulmonary disease]. The %predicted values of FEV1 [median, 63.5 versus 92, P < 0.0001] and FVC [median 61.1 versus 98.5, P < 0.0001] were lower, while the FEV1/FVC ratio (median 106.7 versus 93.7, P < 0.0001) was higher in patients with versus without IIP [defined by high-resolution computed tomography (HRCT) imaging findings [14]]. The clinical diagnoses for patients before TL testing included 107 (42%) IIP, 22 (9%) aplastic anemia, 13 (5%) each with unexplained pancytopenia, immunodeficiency, and IIP/cirrhosis, 12 (5%) cirrhosis, 11 (4%) common variable immunodeficiency (CVID), 8 (3%) each with BMF and lymphopenia, 5 (2%) each with unexplained anemia, bictopenia, and myelodysplastic syndrome, 4 (2%) each with CVID and neutropenia, 3 (1%) with thrombocytopenia, 2 (1%) each with hypersensitivity pneumonitis (HP) and NRH, 1 (<1%) each with CVID/NRH, acute myeloid leukemia, Diamond-Blackfan Anemia, IIP/BMF, IIP/cirrhosis/BMF, IIP/NRH/BMF, IIP/pancytopenia, and leukopenia. Seven (3%) patients were tested only due to a significant family history without an obvious clinical phenotype. CLS stratification included low (n = 139, 55%), intermediate (n = 83, 33%), and high (n = 30, 12%) groups, with higher CLS significantly correlating with lower delta (age-adjusted) TL for lymphocytes (P = 0.01) but not granulocytes (P = 0.1). Genetic testing was performed in 82 (33%) patients (targeted NGS panel-
| Characteristic (median; % or range) | Total (n = 233) | FlowFISH TL centile categories (categorization possible in 233 patients) | P value |
|-----------------------------------|----------------|--------------------------------------------------------------------------------------------------|--------|
|                                   |                | Group A (<1st centile TL in both lymphocytes and granulocytes) (n = 14) |        |
| Age (in years)                    | 58 (4–83)      | 60 (4–77)                                                                                       | 0.04   |
| No. of males (%)                  | 144 (57)       | 56 (57)                                                                                         | 0.1    |
| Family history                    | 63 (25)        | 28 (33)                                                                                         | 0.4    |
| Premature graying of hair (onset at age ≤30 years) | 23 (10) | 11 (13)                                                                                       | 0.2    |
| IP                                | 135 (54)       | 60 (71)                                                                                         |        |
| Cytopenias                         | 103 (44)       | 39 (46)                                                                                         | 0.4    |
| Cirrhosis                          | 28 (12)        | 16 (19)                                                                                         | 0.04   |
| NRH                               | 4 (2)          | 1 (1)                                                                                           | 0.3    |
| Immunodeficiency                  | 37 (16)        | 6 (7)                                                                                           | 0.02   |
| Clinical likelihood of STSa       |                |                                                                                                 |        |
| Low (1)                           | 123 (53)       | 33 (39)                                                                                         | 0.008  |
| Intermediate (2)                  | 81 (35)        | 20 (38)                                                                                         | 0.5    |
| High (>2)                         | 29 (12)        | 24 (29)                                                                                         |        |
| Delta TL in lymphocytes (kb)      |                |                                                                                                 |        |
| −1.12 (−5.11 to 2.62)             | 1.62 (−3.28–0.7) | −1.4 (−2.5–1)                                                                                   | <0.0001|
| Delta TL in granulocytes (kb)     |                |                                                                                                 |        |
| −1.27 (−10.6 to 6.35)             | −1.84 (−10.6–2.29) | −1.1 (−2.5–5.72)                                                                                | <0.0001|
| No. of patients with genetic testingb | 73 (31)     | 29 (35)                                                                                         | 0.03   |
| No. of patients with telomere-related variants |      |                                                                                                 |        |
| Pathogenic/likely pathogenic      | 9 (12)         | 4 (14)                                                                                          | 0.008  |
| VUS                               | 16 (22)        | 3 (20)                                                                                          | 0.9    |

This table includes data on 233 patients out of the total cohort of 252 patients. In 19 patients, data on both lymphocytes and granulocytes was not available for categorization into the TL categories. Significant clinical features for TBD considered were personal history of premature graying of hair (onset at age ≤ 30 years), IPF, unexplained cytopenias, cirrhosis or NRH, and unexplained immunodeficiency, or significant family history of the above (in one or more 1st or 2nd degree relatives).

FlowFISH flow cytometry fluorescence in-situ hybridization, TL telomere length, IIP idiopathic interstitial pneumonia, NRH nodular regenerative hyperplasia, TBD telomere biology disorders, VUS variant of uncertain significance.

Based on the number of the significant clinical features, clinical likelihood score was defined as low (1), intermediate (2), and high (>2).

Included patients were tested with panels designed to test bone marrow failure-related genes. In other words, patients who underwent genetic testing with hematologic malignancy-based next-generation sequencing panels were excluded.

Bold values indicate statistical significance.
Panel, 8 ES-Slices, and 5 WES) of whom only 5 (23%) had VUS in 1 pathogenic variant (underwent genetic testing (2 NGS-panel, 7 ES-Slice, 4 WES) with 4 pathogenic variants (3 RTEL1, 1 RTEL1, 1 TINF2, 1 WRAP53) which was positive for 9 (11%) pathogenic or likely pathogenic (8 TERT and 1 RTEL1) variants and 16 (19.5%) variants of uncertain significance (Supplementary table 2). Since this was a retrospective study, the genetic analyses are limited by the fact that certain patients were more likely to be tested than others based on clinical features. Among patients with short telomeres (TL in lymphocytes ≤10th centile, n = 158, 146 adults), only 17% (9/54 tested patients) were positive for pathogenic variants. This suggests potential alternative, epigenetic or non-genetic mechanisms of telomere shortening/telomere length regulation such as aging-associated methylation and/or chromatin modifications, and environmental factors as suggested in other studies [15, 16]. ‘High risk’ per CLS score (as defined above) was unable to predict likelihood of finding a telomere-associated variant (P = 0.6), highlighting the shortcomings in the predictive value of phenotypic changes/family histories in adult patients with suspected TBDs.

Based on age-appropriate centile categorization of lymphocyte and granulocyte TL (information for both available in 233 patients), patients were stratified into four groups (Table 1). Group A (n = 14) included TL < 1st centile in both lymphocytes and granulocytes. Among the 9 (64%) patients who underwent genetic testing (4 targeted NGS panels, 4 ES-Slice, and 1 WES) in this group, 4 (44%) patients were found to have pathogenic variant (all TERT) and 2 (22%) patients were detected to have a VUS (both RTEL1). Group B included patients with TL 1–10th centile in both lymphocytes and granulocytes, or <1st centile in either lymphocytes or granulocytes (n = 84). Twenty-nine (35%) underwent genetic testing (11 targeted NGS panels, 16 ES-Slice, and 2 WES) with 4 pathogenic variants (3 TERT, 1 RTEL1), and 5 VUS (2 RTEL1, 1 TERT, 1 NHP2, and 1 PARN). Group C included patients with TL 1–10th centile in lymphocytes only and >10th centile in granulocytes (n = 53). Thirteen (25%) patients in this group underwent genetic testing (2 NGS-panel, 7 ES-Slice, 4 WES) with 1 pathogenic variant (TERT) and 3 VUS (2 in TINF2, 1 in RTEL1). Group D included patients with TL >10th centile in lymphocytes (n = 82). Genetic testing was done in 22 (27%) patients (9 NGS-Panel, 8 ES-Slices, and 5 WES) of whom only 5 (23%) had VUS in 2 RTEL1, 1 TINF2, 1 WRAP53, and 1 CTC1, without any bona fide pathogenic variants (Fig. 1A and Table 1). In patients with pulmonary disease, %predicted values of FEV1 (R² = 0.08, P = 0.3), FVC (R² = 0.1, P = 0.2), and FEV1/FVC (R² = 0.1, P = 0.3) did not correlate with the likelihood of finding a telomere-associated pathogenic variant. Interestingly, one 47-year-old patient had FlowFISH testing (at the same laboratory) at three different time points in a span of 6 months (post-transplant), with results demonstrating variability in telomere length measurement (Supplementary table 3) and categorization, which could partly be due to the interassay coefficient of variation for FlowFISH (2.5% for lymphocytes and 2.1% for granulocytes) [10]. For practical clinical decision-making, data for additional categories such as patients with TL <1st centile in lymphocytes and >1st centile in granulocytes, and 1–10th centile in lymphocytes, ≥1st centile in granulocytes is provided in Supplementary table 4.

We then assessed outcomes for patients with TL ≤10th centile in lymphocytes (n = 151). At a median follow-up of 15 (95% CI 13–17) months, 124 (78%) patients were alive with 34 (22%) deaths; higher frequency in non-transplanted (untreated) patients with multiple organ involvement compared with single organ involvement (33 versus 17%, P = 0.02, Fig. 1B). The median Kaplan–Meier estimate of overall survival (OS) was median not reached (95% CI 34–77) versus patients with multiple organ involvement (median not reached in either category, *P = 0.04).

Potential caveats of using FlowFISH testing include interassay variability, measuring only mean TL, lack of ability in measuring tissue-specific TL, and possibility of missing silent genetic carriers who may have TL at the lower end of the normal range. Patients with multiple organ involvement clearly have worse...
outcomes, with multiorgan transplant strategies available at select centers.

Abhishek A. Mangaonkar, Alejandro Ferrer, Filippo Pinto E. Vairo, Caleb W. Hammel, Carri Prochnow, Naseema Gangat, William J. Hogan, Mark R. Litzow, Steve G. Peters, J. P. Scott, James P. Utz, Misbah Baqir, Eva M. Carmona-Porquera, Sanjay Kalra, Hiroshi Sekiguchi, Shakila P. Khan, Douglas A. Simonetto, Eric W. Klee, Patrick S. Kamath, Anja C. Roden, Avni Y. Joshi, Cassie C. Kennedy, Mark E. Wylam and Mrinal M. Patnaik.

Division of Hematology, Department of Medicine, Rochester, MN, USA. Center for Individualized Health Science, Rochester, MN, USA. Department of Clinical Genomics, Rochester, MN, USA. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, MN, USA. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Rochester, MN, USA. Division of Gastroenterology, Department of Medicine, Rochester, MN, USA. Department of Laboratory Medicine and Pathology, Rochester, MN, USA. Division of Pediatric Allergy and Immunology, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.

These authors contributed equally: Abhishek A. Mangaonkar, Alejandro Ferrer. 

Email: patnaik.mrinal@mayo.edu

REFERENCES

1. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telom eropathies. Blood. 2014;124:2775–83.
2. Heiss NS, Knight SW, Vulliamy TJ, Klaucz SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19:32–38.
3. Calado RT, Young NS. Telomere diseases. New Engl J Med. 2009;361:2353–65.
4. Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Klee EW, et al. Clinical correlates and treatment outcomes for patients with short telomere syndromes. Mayo Clin Proc. 2018;93:834–9.
5. Mangaonkar AA, Patnaik MM. Short telomere syndromes in clinical practice: bridging bench and bedside. Mayo Clin Proc. 2018;93:904–16.
6. Feurstein S, Adegunsoyo A, Mojilislov D, Vj R, West DePersia AH, Rajagopal PS, et al. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020;4:873–86.
7. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. New Engl J Med. 2007;356:1317–26.
8. Calado RT, Hegel JA, Kleiner DE, Schrump DS, Peterson NR, Pons V, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS ONE. 2009;4:e7926.
9. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30–39.
10. Alder JK, Hanumanthu VS, Strong MA, DeZern AE, Stanley SE, Takemoto CM, et al. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci USA. 2018;115:E2358–e2365.
11. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc. 2006;1:2365–76.
12. Ferrer A, Mangaonkar AA, Stroik S, Zimmermann MT, Sigafoos AN, Kamath PS, et al. Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer J. 2020;10:120.

ACKNOWLEDGEMENTS

Authors acknowledge support from the Mayo Clinic Center for Individualized Medicine. Authors would like to acknowledge and thank the referral testing laboratories (Johns Hopkins Medical Laboratories in Baltimore, MD and RepeatDx in Vancouver, Canada).

AUTHOR CONTRIBUTIONS

AAM wrote the initial and subsequent drafts of the manuscript, and performed data extraction and analysis. AF performed a part of the data extraction and edited the manuscript. FPV, CWHP, CP, NG, WJH, MRL, SGP, JPS, JPU, MB, ECP, SK, HS, SPK, DAS, EWK, PSK, ACR, AJY, CCK, and MEW contributed patients and edited the manuscript. MMP supervised the study and edited all drafts of the manuscript.

CONFLICT OF INTEREST

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-021-00564-7.

Correspondence and requests for materials should be addressed to Mrinal M. Patnaik.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021